MargaretAnn Cross

Society must realize that health care resources are limited and then must use them rationally. Fairly, too?

Medical ethicists believe the United States needs to have a forthright public debate about how to spend limited health care resources wisely. We simply can't pay for everything, so we must — as a country — decide what is worth paying for and what isn't, they argue.

Can consumer-directed plans, with their emphasis on giving people a stake in health care costs, play a role in forming that public discussion?

They just might, says James Sabin, MD, a medical ethicist and psychiatrist who runs the ethics advisory group at Harvard Pilgrim Health Care. "The consumer-driven idea has the potential of being a kind of schooling for consumers, guiding them toward thinking in value-oriented terms about health care."

People are not going to shop for acute hospital care for crushing chest pain, he says. "But they will think about things such as, 'If I'm getting an elective MRI, how much does it cost at different sites and is there a differential value, and if so, how much is it worth?' That will be a good thing."

For several decades, insurance has insulated people from coming to grips with the need to make trade-offs, Sabin says. If society can see the ethical need to make values-based choices, rather than believing that health care resources are unlimited, "that's a step forward."

Yet the problem with consumer-directed health care is that it only requires people to think individually — rather than collectively — about health care choices, says Leonard M. Fleck, PhD, a professor of philosophy and medical ethics at Michigan State University. "We can't as a moral and a practical matter decide individually what kind of rationing choices we'd be willing to embrace," he says. "You need some kind of consistency and coherence with regard to the kinds of rationing decisions that need to be made, and I'm not confident that an individualized consumer-directed mode is the way to bring that about."

Consumers' ignorance about prices and the fact that they sometimes seek care that is unnecessary — both of which the new plans are designed to address — are only a small part of the problem of escalating health care costs, says Karen Gervais, PhD, director of the Minnesota Center for Health Care Ethics. "I don't think it's going to do a great deal of good to educate consumers about cost. When you are sick, you can't control your utilization."

Some people, however, may become activists based on their individual experiences, Sabin suggests. "They are going to ask important questions."

To make a real difference, consumers need to be educated about and involved in much larger policy questions — such as when it is appropriate for an insurance company to begin covering a new device or procedure — rather than how much an MRI costs, Gervais says. Insurers are often pressured to pay for expensive, unproven treatments, which has a huge impact on the cost of health care, she explains. "If consumers could really see what that choice amounts to and what the cost and patient safety implications are, they might think it through differently. It's a huge educational task, and can't be delivered in sound bites. It needs a good, solid conversation."

The moral issue that is at stake for these public discussions is health care justice, says Fleck. "Even though this year we will probably spend about $1.6 trillion on health care, that doesn't buy everything that is needed in the way of health care for all Americans. We have 43 million uninsured, a lot who are underinsured and a lot who are denied health care because they can't afford it. Other people spend extravagantly — often public Medicare and Medicaid dollars — on health care that is only marginally beneficial, as when patients demand heavily advertised drugs from their physicians when generic versions would work equally well at a small fraction of the cost. There is something that is fundamentally unjust about that state of affairs. A society that is just and caring ought to do better than that."

MargaretAnn Cross

Special Issue on Consumer-Directed Health Care

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.